| Q35357838 | A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells |
| Q34493542 | Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer |
| Q35349490 | Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer |
| Q46591244 | C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype |
| Q34984681 | CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells |
| Q30427752 | Calpain-mediated proteolysis of paxillin negatively regulates focal adhesion dynamics and cell migration |
| Q30497846 | Chemo-Resistant Protein Expression Pattern of Glioblastoma Cells (A172) to Perillyl Alcohol |
| Q42374132 | Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies |
| Q35206363 | DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer |
| Q35940252 | Deciphering Mode of Action of Functionally Important Regions in the Intrinsically Disordered Paxillin (Residues 1-313) Using Its Interaction with FAT (Focal Adhesion Targeting Domain of Focal Adhesion Kinase). |
| Q38694303 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. |
| Q36443392 | Diverse roles for the paxillin family of proteins in cancer |
| Q39048792 | Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer |
| Q34219445 | Emerging role of paxillin-PKL in regulation of cell adhesion, polarity and migration |
| Q41161511 | Evaluation of paxillin expression in patients with oral squamous cell carcinoma: An immunohistochemical study |
| Q92240291 | Expression of Paxillin in Benign and Malignant Salivary Gland Tumors |
| Q35871428 | Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer Patients |
| Q36095220 | Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value |
| Q42651022 | Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung |
| Q26765360 | FAK and paxillin, two potential targets in pancreatic cancer |
| Q34500644 | Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. |
| Q35413993 | HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma |
| Q95841084 | Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing |
| Q24646348 | Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T |
| Q39809313 | Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression |
| Q34182679 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma |
| Q37232416 | MET as a target for treatment of chest tumors |
| Q38389999 | MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications |
| Q28272688 | MET molecular mechanisms and therapies in lung cancer |
| Q37427292 | MET pathway as a therapeutic target |
| Q38419681 | MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance |
| Q38875145 | MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells |
| Q39361908 | Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now? |
| Q37051546 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma |
| Q102141804 | Mutational drivers of cancer cell migration and invasion |
| Q36212445 | Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis |
| Q39380579 | Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. |
| Q44616724 | Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas |
| Q37702693 | Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression |
| Q28297509 | Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease |
| Q42095789 | Paxillin expression is closely linked to the pathogenesis, progression and prognosis of gastric carcinomas |
| Q36068321 | Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation |
| Q28478399 | Paxillin mediates sensing of physical cues and regulates directional cell motility by controlling lamellipodia positioning |
| Q30542819 | Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer |
| Q35832209 | Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87. |
| Q37650990 | Paxillin: a crossroad in pathological cell migration |
| Q39085744 | Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression |
| Q47122996 | Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression |
| Q28391454 | Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database |
| Q35146597 | RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma |
| Q31154012 | Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer |
| Q39839983 | Role of c-Met in cancer: emphasis on lung cancer |
| Q27027957 | Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents |
| Q33763551 | Significance of talin in cancer progression and metastasis |
| Q39458579 | Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. |
| Q24609682 | The MET axis as a therapeutic target |
| Q30494514 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma |
| Q35146937 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy |
| Q26998420 | c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade |
| Q39062167 | miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin |
| Q34721988 | p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. |